Pinnacle Dialysis Of Boca Raton is a medicare approved dialysis facility center in Boca Raton, Florida and it has 27 dialysis stations. It is located in Palm Beach county at 2900 N Military Trail Suite 195, Boca Raton, FL, 33431. You can reach out to the office of Pinnacle Dialysis Of Boca Raton at (561) 241-6667. This dialysis clinic is managed and/or owned by Davita. Pinnacle Dialysis Of Boca Raton has the following ownership type - Profit. It was first certified by medicare in June, 1993. The medicare id for this facility is 102658 and it accepts patients under medicare ESRD program.
| Name | Pinnacle Dialysis Of Boca Raton |
|---|---|
| Location | 2900 N Military Trail Suite 195, Boca Raton, Florida |
| No. of Dialysis Stations | 27 |
| Medicare ID | 102658 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | Yes |
| 2900 N Military Trail Suite 195, Boca Raton, Florida, 33431 | |
| (561) 241-6667 | |
News Archive
House Appropriations Chairman Harold Rogers (R-Ky.) said on Thursday that Republicans had reached an agreement with Democrats to reduce the the number of pending amendments to a bill that would fund the government through the end of the current fiscal year, CQ reports (Carter, 2/17). "A final vote on the 2011 budget measure may come as soon as today. It then would go to the Senate, where the Democratic majority is likely to reject the proposal, raising the prospect of a government shutdown," Bloomberg Businessweek reports (Faler, 2/18).
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients.
After the scare that some French breast implants may be faulty and may need removal at the government's expense the national health insurance agency will file a criminal complaint. The implants, made by now-defunct French company Poly Implant Prothese (PIP), were pulled from the market last year in countries around Europe and South America amid fears they could rupture and leak silicone into the body.
With Senate and House leaders trying to craft a health care reform bill to send to the White House, the National Community Pharmacists Association (NCPA) today offered lawmakers updated recommendations for the would-be final legislation.
› Verified 7 days ago
| NPI Number | 1639162829 |
| Organization Name | Dialysis Of Boca Delray |
| Doing Business As | Pinnacle Dialysis Inc |
| Address | 2900 N Military Trl Boca Raton, Florida, 33431 |
| Phone Number | (561) 241-6667 |
News Archive
House Appropriations Chairman Harold Rogers (R-Ky.) said on Thursday that Republicans had reached an agreement with Democrats to reduce the the number of pending amendments to a bill that would fund the government through the end of the current fiscal year, CQ reports (Carter, 2/17). "A final vote on the 2011 budget measure may come as soon as today. It then would go to the Senate, where the Democratic majority is likely to reject the proposal, raising the prospect of a government shutdown," Bloomberg Businessweek reports (Faler, 2/18).
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients.
After the scare that some French breast implants may be faulty and may need removal at the government's expense the national health insurance agency will file a criminal complaint. The implants, made by now-defunct French company Poly Implant Prothese (PIP), were pulled from the market last year in countries around Europe and South America amid fears they could rupture and leak silicone into the body.
With Senate and House leaders trying to craft a health care reform bill to send to the White House, the National Community Pharmacists Association (NCPA) today offered lawmakers updated recommendations for the would-be final legislation.
› Verified 7 days ago
| NPI Number | 1871748087 |
| Organization Name | Pinnacle Dialysis Of Boca Raton |
| Doing Business As | Total Renal Care Inc |
| Address | 2900 N Military Trl Ste 195 Boca Raton, Florida, 33431 |
| Phone Number | (561) 241-6667 |
News Archive
House Appropriations Chairman Harold Rogers (R-Ky.) said on Thursday that Republicans had reached an agreement with Democrats to reduce the the number of pending amendments to a bill that would fund the government through the end of the current fiscal year, CQ reports (Carter, 2/17). "A final vote on the 2011 budget measure may come as soon as today. It then would go to the Senate, where the Democratic majority is likely to reject the proposal, raising the prospect of a government shutdown," Bloomberg Businessweek reports (Faler, 2/18).
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients.
After the scare that some French breast implants may be faulty and may need removal at the government's expense the national health insurance agency will file a criminal complaint. The implants, made by now-defunct French company Poly Implant Prothese (PIP), were pulled from the market last year in countries around Europe and South America amid fears they could rupture and leak silicone into the body.
With Senate and House leaders trying to craft a health care reform bill to send to the White House, the National Community Pharmacists Association (NCPA) today offered lawmakers updated recommendations for the would-be final legislation.
› Verified 7 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 67% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 21% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 12% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 76% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 18% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 6% | 14% |
News Archive
House Appropriations Chairman Harold Rogers (R-Ky.) said on Thursday that Republicans had reached an agreement with Democrats to reduce the the number of pending amendments to a bill that would fund the government through the end of the current fiscal year, CQ reports (Carter, 2/17). "A final vote on the 2011 budget measure may come as soon as today. It then would go to the Senate, where the Democratic majority is likely to reject the proposal, raising the prospect of a government shutdown," Bloomberg Businessweek reports (Faler, 2/18).
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients.
After the scare that some French breast implants may be faulty and may need removal at the government's expense the national health insurance agency will file a criminal complaint. The implants, made by now-defunct French company Poly Implant Prothese (PIP), were pulled from the market last year in countries around Europe and South America amid fears they could rupture and leak silicone into the body.
With Senate and House leaders trying to craft a health care reform bill to send to the White House, the National Community Pharmacists Association (NCPA) today offered lawmakers updated recommendations for the would-be final legislation.
› Verified 7 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 66% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 21% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 13% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 76% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 21% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 3% | 12% |
News Archive
House Appropriations Chairman Harold Rogers (R-Ky.) said on Thursday that Republicans had reached an agreement with Democrats to reduce the the number of pending amendments to a bill that would fund the government through the end of the current fiscal year, CQ reports (Carter, 2/17). "A final vote on the 2011 budget measure may come as soon as today. It then would go to the Senate, where the Democratic majority is likely to reject the proposal, raising the prospect of a government shutdown," Bloomberg Businessweek reports (Faler, 2/18).
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients.
After the scare that some French breast implants may be faulty and may need removal at the government's expense the national health insurance agency will file a criminal complaint. The implants, made by now-defunct French company Poly Implant Prothese (PIP), were pulled from the market last year in countries around Europe and South America amid fears they could rupture and leak silicone into the body.
With Senate and House leaders trying to craft a health care reform bill to send to the White House, the National Community Pharmacists Association (NCPA) today offered lawmakers updated recommendations for the would-be final legislation.
› Verified 7 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 78% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 22% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 74% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 22% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 4% | 12% |
News Archive
House Appropriations Chairman Harold Rogers (R-Ky.) said on Thursday that Republicans had reached an agreement with Democrats to reduce the the number of pending amendments to a bill that would fund the government through the end of the current fiscal year, CQ reports (Carter, 2/17). "A final vote on the 2011 budget measure may come as soon as today. It then would go to the Senate, where the Democratic majority is likely to reject the proposal, raising the prospect of a government shutdown," Bloomberg Businessweek reports (Faler, 2/18).
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients.
After the scare that some French breast implants may be faulty and may need removal at the government's expense the national health insurance agency will file a criminal complaint. The implants, made by now-defunct French company Poly Implant Prothese (PIP), were pulled from the market last year in countries around Europe and South America amid fears they could rupture and leak silicone into the body.
With Senate and House leaders trying to craft a health care reform bill to send to the White House, the National Community Pharmacists Association (NCPA) today offered lawmakers updated recommendations for the would-be final legislation.
› Verified 7 days ago
| Dialysis patients with Hemoglobin data | 70 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 6 |
News Archive
House Appropriations Chairman Harold Rogers (R-Ky.) said on Thursday that Republicans had reached an agreement with Democrats to reduce the the number of pending amendments to a bill that would fund the government through the end of the current fiscal year, CQ reports (Carter, 2/17). "A final vote on the 2011 budget measure may come as soon as today. It then would go to the Senate, where the Democratic majority is likely to reject the proposal, raising the prospect of a government shutdown," Bloomberg Businessweek reports (Faler, 2/18).
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients.
After the scare that some French breast implants may be faulty and may need removal at the government's expense the national health insurance agency will file a criminal complaint. The implants, made by now-defunct French company Poly Implant Prothese (PIP), were pulled from the market last year in countries around Europe and South America amid fears they could rupture and leak silicone into the body.
With Senate and House leaders trying to craft a health care reform bill to send to the White House, the National Community Pharmacists Association (NCPA) today offered lawmakers updated recommendations for the would-be final legislation.
› Verified 7 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 106 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 850 |
| Percentage of adult patients getting regular hemodialysis at the center | 98 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
House Appropriations Chairman Harold Rogers (R-Ky.) said on Thursday that Republicans had reached an agreement with Democrats to reduce the the number of pending amendments to a bill that would fund the government through the end of the current fiscal year, CQ reports (Carter, 2/17). "A final vote on the 2011 budget measure may come as soon as today. It then would go to the Senate, where the Democratic majority is likely to reject the proposal, raising the prospect of a government shutdown," Bloomberg Businessweek reports (Faler, 2/18).
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients.
After the scare that some French breast implants may be faulty and may need removal at the government's expense the national health insurance agency will file a criminal complaint. The implants, made by now-defunct French company Poly Implant Prothese (PIP), were pulled from the market last year in countries around Europe and South America amid fears they could rupture and leak silicone into the body.
With Senate and House leaders trying to craft a health care reform bill to send to the White House, the National Community Pharmacists Association (NCPA) today offered lawmakers updated recommendations for the would-be final legislation.
› Verified 7 days ago
| Adult patients getting regular peritoneal dialysis at the center | 13 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 93 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 94 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
House Appropriations Chairman Harold Rogers (R-Ky.) said on Thursday that Republicans had reached an agreement with Democrats to reduce the the number of pending amendments to a bill that would fund the government through the end of the current fiscal year, CQ reports (Carter, 2/17). "A final vote on the 2011 budget measure may come as soon as today. It then would go to the Senate, where the Democratic majority is likely to reject the proposal, raising the prospect of a government shutdown," Bloomberg Businessweek reports (Faler, 2/18).
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients.
After the scare that some French breast implants may be faulty and may need removal at the government's expense the national health insurance agency will file a criminal complaint. The implants, made by now-defunct French company Poly Implant Prothese (PIP), were pulled from the market last year in countries around Europe and South America amid fears they could rupture and leak silicone into the body.
With Senate and House leaders trying to craft a health care reform bill to send to the White House, the National Community Pharmacists Association (NCPA) today offered lawmakers updated recommendations for the would-be final legislation.
› Verified 7 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Pinnacle Dialysis Of Boca Raton with elevated calcium levels.
| Patients with hypercalcemia | 121 |
| Hypercalcemia patient months | 992 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 133 |
| Patients with Serumphosphor less than 3.5 mg/dL | 10 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 23 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 28 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 25 |
| Patients with Serumphosphor greater than 7 mg/dL | 14 |
News Archive
House Appropriations Chairman Harold Rogers (R-Ky.) said on Thursday that Republicans had reached an agreement with Democrats to reduce the the number of pending amendments to a bill that would fund the government through the end of the current fiscal year, CQ reports (Carter, 2/17). "A final vote on the 2011 budget measure may come as soon as today. It then would go to the Senate, where the Democratic majority is likely to reject the proposal, raising the prospect of a government shutdown," Bloomberg Businessweek reports (Faler, 2/18).
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients.
After the scare that some French breast implants may be faulty and may need removal at the government's expense the national health insurance agency will file a criminal complaint. The implants, made by now-defunct French company Poly Implant Prothese (PIP), were pulled from the market last year in countries around Europe and South America amid fears they could rupture and leak silicone into the body.
With Senate and House leaders trying to craft a health care reform bill to send to the White House, the National Community Pharmacists Association (NCPA) today offered lawmakers updated recommendations for the would-be final legislation.
› Verified 7 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 129 |
| Patient months included in arterial venous fistula and catheter summaries | 835 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 62 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 7 |
News Archive
House Appropriations Chairman Harold Rogers (R-Ky.) said on Thursday that Republicans had reached an agreement with Democrats to reduce the the number of pending amendments to a bill that would fund the government through the end of the current fiscal year, CQ reports (Carter, 2/17). "A final vote on the 2011 budget measure may come as soon as today. It then would go to the Senate, where the Democratic majority is likely to reject the proposal, raising the prospect of a government shutdown," Bloomberg Businessweek reports (Faler, 2/18).
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients.
After the scare that some French breast implants may be faulty and may need removal at the government's expense the national health insurance agency will file a criminal complaint. The implants, made by now-defunct French company Poly Implant Prothese (PIP), were pulled from the market last year in countries around Europe and South America amid fears they could rupture and leak silicone into the body.
With Senate and House leaders trying to craft a health care reform bill to send to the White House, the National Community Pharmacists Association (NCPA) today offered lawmakers updated recommendations for the would-be final legislation.
› Verified 7 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 111 |
| Hospitalization Rate in facility | 148.4 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 258.5 |
| Hospitalization Rate: Lower Confidence Limit | 92.7 |
News Archive
House Appropriations Chairman Harold Rogers (R-Ky.) said on Thursday that Republicans had reached an agreement with Democrats to reduce the the number of pending amendments to a bill that would fund the government through the end of the current fiscal year, CQ reports (Carter, 2/17). "A final vote on the 2011 budget measure may come as soon as today. It then would go to the Senate, where the Democratic majority is likely to reject the proposal, raising the prospect of a government shutdown," Bloomberg Businessweek reports (Faler, 2/18).
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients.
After the scare that some French breast implants may be faulty and may need removal at the government's expense the national health insurance agency will file a criminal complaint. The implants, made by now-defunct French company Poly Implant Prothese (PIP), were pulled from the market last year in countries around Europe and South America amid fears they could rupture and leak silicone into the body.
With Senate and House leaders trying to craft a health care reform bill to send to the White House, the National Community Pharmacists Association (NCPA) today offered lawmakers updated recommendations for the would-be final legislation.
› Verified 7 days ago
The rate of readmission show you whether patients who were being treated regularly at Pinnacle Dialysis Of Boca Raton were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 24.8 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 34 |
| Readmission Rate: Lower Confidence Limit | 17 |
News Archive
House Appropriations Chairman Harold Rogers (R-Ky.) said on Thursday that Republicans had reached an agreement with Democrats to reduce the the number of pending amendments to a bill that would fund the government through the end of the current fiscal year, CQ reports (Carter, 2/17). "A final vote on the 2011 budget measure may come as soon as today. It then would go to the Senate, where the Democratic majority is likely to reject the proposal, raising the prospect of a government shutdown," Bloomberg Businessweek reports (Faler, 2/18).
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients.
After the scare that some French breast implants may be faulty and may need removal at the government's expense the national health insurance agency will file a criminal complaint. The implants, made by now-defunct French company Poly Implant Prothese (PIP), were pulled from the market last year in countries around Europe and South America amid fears they could rupture and leak silicone into the body.
With Senate and House leaders trying to craft a health care reform bill to send to the White House, the National Community Pharmacists Association (NCPA) today offered lawmakers updated recommendations for the would-be final legislation.
› Verified 7 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Pinnacle Dialysis Of Boca Raton get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .9 (As Expected) |
| SIR: Upper Confidence Limit | 1.98 |
| SIR: Lower Confidence Limit | .33 |
News Archive
House Appropriations Chairman Harold Rogers (R-Ky.) said on Thursday that Republicans had reached an agreement with Democrats to reduce the the number of pending amendments to a bill that would fund the government through the end of the current fiscal year, CQ reports (Carter, 2/17). "A final vote on the 2011 budget measure may come as soon as today. It then would go to the Senate, where the Democratic majority is likely to reject the proposal, raising the prospect of a government shutdown," Bloomberg Businessweek reports (Faler, 2/18).
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients.
After the scare that some French breast implants may be faulty and may need removal at the government's expense the national health insurance agency will file a criminal complaint. The implants, made by now-defunct French company Poly Implant Prothese (PIP), were pulled from the market last year in countries around Europe and South America amid fears they could rupture and leak silicone into the body.
With Senate and House leaders trying to craft a health care reform bill to send to the White House, the National Community Pharmacists Association (NCPA) today offered lawmakers updated recommendations for the would-be final legislation.
› Verified 7 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Pinnacle Dialysis Of Boca Raton's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 77 |
| Transfusion Rate in facility | 26.8 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 71.4 |
| Transfusion Rate: Lower Confidence Limit | 11.3 |
News Archive
House Appropriations Chairman Harold Rogers (R-Ky.) said on Thursday that Republicans had reached an agreement with Democrats to reduce the the number of pending amendments to a bill that would fund the government through the end of the current fiscal year, CQ reports (Carter, 2/17). "A final vote on the 2011 budget measure may come as soon as today. It then would go to the Senate, where the Democratic majority is likely to reject the proposal, raising the prospect of a government shutdown," Bloomberg Businessweek reports (Faler, 2/18).
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients.
After the scare that some French breast implants may be faulty and may need removal at the government's expense the national health insurance agency will file a criminal complaint. The implants, made by now-defunct French company Poly Implant Prothese (PIP), were pulled from the market last year in countries around Europe and South America amid fears they could rupture and leak silicone into the body.
With Senate and House leaders trying to craft a health care reform bill to send to the White House, the National Community Pharmacists Association (NCPA) today offered lawmakers updated recommendations for the would-be final legislation.
› Verified 7 days ago
The rate of mortality show you whether patients who were being treated regularly at Pinnacle Dialysis Of Boca Raton lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 531 |
| Mortality Rate in facility | 13.7 (Better than Expected) |
| Mortality Rate: Upper Confidence Limit | 17 |
| Mortality Rate: Lower Confidence Limit | 10.9 |
News Archive
House Appropriations Chairman Harold Rogers (R-Ky.) said on Thursday that Republicans had reached an agreement with Democrats to reduce the the number of pending amendments to a bill that would fund the government through the end of the current fiscal year, CQ reports (Carter, 2/17). "A final vote on the 2011 budget measure may come as soon as today. It then would go to the Senate, where the Democratic majority is likely to reject the proposal, raising the prospect of a government shutdown," Bloomberg Businessweek reports (Faler, 2/18).
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients.
After the scare that some French breast implants may be faulty and may need removal at the government's expense the national health insurance agency will file a criminal complaint. The implants, made by now-defunct French company Poly Implant Prothese (PIP), were pulled from the market last year in countries around Europe and South America amid fears they could rupture and leak silicone into the body.
With Senate and House leaders trying to craft a health care reform bill to send to the White House, the National Community Pharmacists Association (NCPA) today offered lawmakers updated recommendations for the would-be final legislation.
› Verified 7 days ago
Boca Raton Artificial Kidney Center Location: 998 Nw 9th Ct, Boca Raton, Florida, 33486 Phone: (561) 392-3940 |
West Boca Dialysis Center Location: 19801 Hampton Dr, Boca Raton, Florida, 33434 Phone: (561) 488-0202 |
Pinnacle Dialysis Of Boca Raton Location: 2900 N Military Trail Suite 195, Boca Raton, Florida, 33431 Phone: (561) 241-6667 |
Boca/Delray Renal Associates Inc Location: 1905 Clint Moore Rd Ste 306, Boca Raton, Florida, 33496 Phone: (561) 988-7100 |
ARA - Boca Raton Dialysis Llc Location: 1905 Clint Moore Rd Ste 211, Boca Raton, Florida, 33496 Phone: (561) 893-6878 |
News Archive
House Appropriations Chairman Harold Rogers (R-Ky.) said on Thursday that Republicans had reached an agreement with Democrats to reduce the the number of pending amendments to a bill that would fund the government through the end of the current fiscal year, CQ reports (Carter, 2/17). "A final vote on the 2011 budget measure may come as soon as today. It then would go to the Senate, where the Democratic majority is likely to reject the proposal, raising the prospect of a government shutdown," Bloomberg Businessweek reports (Faler, 2/18).
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients.
After the scare that some French breast implants may be faulty and may need removal at the government's expense the national health insurance agency will file a criminal complaint. The implants, made by now-defunct French company Poly Implant Prothese (PIP), were pulled from the market last year in countries around Europe and South America amid fears they could rupture and leak silicone into the body.
With Senate and House leaders trying to craft a health care reform bill to send to the White House, the National Community Pharmacists Association (NCPA) today offered lawmakers updated recommendations for the would-be final legislation.
› Verified 7 days ago